Therapeutic vitamin combinations classified as medicaments under Chapter 30 rather than vitamins under Chapter 29.

Fixed dose combinations of vitamins B1, B6 and B12 in tablet and injection form are classifiable under Chapter 30 as medicaments when they have therapeutic or prophylactic use and are marketed as branded formulations. The Tribunal preferred Chapter 30 over Chapter 29 because the Chapter Note defines medicaments by therapeutic or prophylactic purpose, and Rule 3(c) supported that classification. It also noted that any prohibition under the Drugs & Cosmetics Act does not, by itself, negate therapeutic or prophylactic value for excise classification. The result was classification under Chapter 30, not as vitamins under Chapter 29.

---

---

Issues: Classification of fixed dose combinations of vitamins B1, B6 and B12 in tablet and injection form, and whether such products fall under Chapter 30 as medicaments or under Chapter 29 as vitamins.

Analysis: The competing decisions considered whether the products were merely vitamin preparations or medicaments put up in measured doses for therapeutic or prophylactic use. The Tribunal preferred the view that Chapter 30 applies where the formulation has prophylactic utility and is marketed as a branded product, and relied on the Chapter Note defining medicaments by therapeutic or prophylactic use. It also noted that the prohibition under the Drugs & Cosmetics Act did not negate the existence of therapeutic or prophylactic value for excise classification purposes. The interpretative principle under Rule 3(c) further supported classification under Chapter 30.

Conclusion: The fixed dose combinations of vitamins B1, B6 and B12 are correctly classifiable under Chapter 30 as medicaments, not under Chapter 29 as vitamins.

Final Conclusion: The reference was answered by upholding the Chapter 30 classification and rejecting the contrary Chapter 29 view.

Ratio Decidendi: For excise classification, a vitamin formulation with therapeutic or prophylactic use, especially when put up as a branded medicament, falls under Chapter 30 rather than Chapter 29.

---